# A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

> **NCT02858440** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 235 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** Infanrix-IPV/Hib

## Key facts

- **NCT ID:** NCT02858440
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-13
- **Primary completion:** 2017-10-24
- **Final completion:** 2018-11-13
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858440, "A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02858440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*